[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vertigo\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vertigo":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,49,81,113,135,158,182,209,242,268,298,341,365,387,416,442],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100467352","fall-risk-assessment-and-speech-intelligibility-enhancement-using-in-ear-device-100467352",false,"NCT05365646","Fall Risk Assessment and Speech Intelligibility Enhancement Using In-ear Device","Inclusion Criteria:\n\n* Age 55 years or older\n* Bilateral hearing aid user\n* Able to consent in English\n* Having access to a phone capable of running the mobile app required for the study\n* Screen for fall risk (\"Yes\" to any question: Feels unsteady when standing or walking? Worries about falling? Has fallen in past year? If the participant has fallen: how many times? were they injured\u002Fhurt?)\n* Ambulatory without need for a wheelchair\n\nExclusion Criteria:\n\n* People with mobility restrictions (e.g., wheelchair bound) that would prevent the performance of the functional assessments.\n* People with severe movement (e.g., Advanced Parkinson's disease) or cognitive (e.g., advanced dementia) disorders that would prevent the individual from either performing the functional assessments, or would lead to restricted activities that would prevent motion data from being collected according to the goal of the study.\n* Inability to understand, consent, and complete requirements including verbal instructions and non-ambulatory\u002Fwheelchair-dependent.",true,"ALL","55 Years",{"count":19,"type":20},350,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to develop and validate methods to use hearing aids equipped with embedded sensors and artificial intelligence to assist in the assessment of fall risk and in the implementation of interventions aimed at reducing the risk of falling, as well as to improve speech intelligibility in quiet and in background noise, track physical activity, and social engagement. The investigators hope is that the knowledge that is generated through this study will ultimately translate to the clinical setting and will help reduce the likelihood that individuals experience a fall, and improve the quality of hearing in individuals who wear hearing aids.",[26,27,28,29,30,31,32],"Hearing Loss","Dizziness","Vertigo","Fall Related Injury Risk","Fall Prevention","Imbalance","Speech Intelligibility",[34,35],"Fall risk","Hearing loss","RECRUITING","2026-04-25",{"date":39,"type":40},"2026-04-28","ACTUAL",{"date":42,"type":40},"2022-05-23",{"date":44,"type":20},"2026-10",{"name":46,"class":47},"Stanford University","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":15,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":60,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":48},"100632775","genetic-and-biohumoral-factors-involved-in-menires-disease-and-their-correlation-with-phenotypes-100632775","NCT07518069","Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes","Genetics and Biohumoral Factors in Menière's Disease","Menière09","Inclusion Criteria:\n\n* Patients with definite Menière's Disease according to the criteria of the Barany Society\n\nExclusion Criteria:\n\n* surgically treated before the examination or if they had undergone intratympanic therapy with steroids or gentamicin","18 Years",{"count":59,"type":20},250,"6 Months","OBSERVATIONAL","Aim of this work was to assess the role of polymorphisms belonging to genes involved in the regulation of ionic homeostasis in Caucasian patients with Ménière Disease (MD) and compare results with a cohort of patients affected by vestibular migraine and a cohort of non vestibular subjects",[28,64,65],"Meniere's Disease","Vestibular Migraine",[67,68,69,70,71],"episodic vertigo","Menière's Disease","Vestibular migraine","genetics","biohumoral markers","2026-04-01",{"date":74,"type":40},"2026-04-08",{"date":76,"type":40},"2025-04-09",{"date":78,"type":20},"2027-04-12",{"name":80,"class":47},"IRCCS San Raffaele",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":48},"100625387","prospective-registry-of-vertigo-due-to-vertebrobasilar-transient-attacks-100625387","NCT07421973","Prospective Registry of Vertigo Due to Vertebrobasilar Transient Attacks.","The UTRAVERA: a Multicenter Prospective Observational Investigation on Vertigo and Dizziness Due to Vertebrobasilar Transient Neurological Attacks - Diagnoses, Clinical Features, Treatment Responses, and Prognostic Factors.","UTRAVERA","Inclusion Criteria:\n\n* Episodic acute vertigo, dizziness or unsteadiness transient or in evolution, therefore, lasting \\\u003C24 h\n* Such an episode may be isolated or associated with one or more of the following:\n\n  1. focal central neurological symptoms or severe postural instability;\n  2. new-onset, moderate-to-severe craniocervical pain; or\n  3. symptoms that are not better accounted for by another disease or disorder.\n\nExclusion Criteria:\n\n* Patients who present with findings of acute hemorrhage or ischemia on the cranial magnetic resonance imaging (MRI), including diffusion-weighted MRI (DWI-MRI) at recruitment;\n* Patients who also fulfill the diagnostic criteria for other neurotological diseases that may present acute or recurrent transient dizziness\u002FVertigo (Unilateral Vestibulopathy; benign paroxysmal positional vertigo; Meniére's disease; Vestibular Migraine; Vestibular Paroxysmia; Persistente Postural-Perceptual Dizziness; and Postural Hypotension;\n* Patients whose symptoms last more than 24 hours or who have evidence of sequelae during follow-up;\n* Patients with contraindications to any of the therapeutic options proposed by this study method;\n* Patients who have other symptoms during the follow-up that suggest another etiology of dizziness or vertigo;\n* Patients who do not complete the entire evaluation;\n* Patients who refuse to sign the informed consent form.",{"count":90,"type":20},400,"Vertigo and dizziness are common neurological complaints in the emergency department and may represent a wide spectrum of etiologies, including vertebrobasilar transient neurological attacks (VB-TNAs). Distinguishing VB-TNAs, particularly vertebrobasilar transient ischemic attacks (VB-TIAs), from migraine-like and other non-vascular conditions is often challenging at first presentation due to the absence of specific biomarkers and overlapping clinical features. The UTRAVERA study is a multicenter, prospective, observational investigation designed to characterize the clinical features of patients presenting with acute transient vertigo or dizziness suspected to be VB-TNAs. The study will also evaluate diagnostic evolution over time, treatment responses, and prognostic factors associated with clinical outcomes.",[28,27,93,94],"TIA (Transient Ischemic Attack)","Transient Neurologic Symptoms",[96,97,98,99,100,101,102],"vertigo and dizziness","Vertebrobasilar Transient Neurological Attack","TIA","Vestibular Symptom","Diagnostic Accuracy","Prognostic Factors","Emergency Department","NOT_YET_RECRUITING","2026-02-24",{"date":106,"type":40},"2026-02-27",{"date":108,"type":20},"2026-05-01",{"date":110,"type":20},"2028-10",{"name":112,"class":47},"University of Sao Paulo General Hospital",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":123,"conditions":124,"keywords":125,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":48},"100615967","diagnostic-aid-for-vertigo-patients-100615967","NCT07299487","Diagnostic Aid for Vertigo Patients","Evaluation of a Diagnostic Aid Tool for the Management of Vertigo Patients for General Practitioners : A Retrospective, Single-center Study at the Strasbourg University Hospital.","ADPV","Inclusion Criteria:\n\n* Subject of legal age (≥18 years)\n* Having received initial care from a medical student and whose consultation data, interview, clinical examination, and diagnosis according to our decision tree were present in the patient file.\n* Patient for whom a definitive diagnosis was made by the on-call ENT physician during the same hospital visit.\n\nExclusion Criteria:\n\n* Subject who expressed objection to the reuse of their data for scientific research.\n* Known chronic vestibular pathology\n* Incomplete patient medical file\n* Patient examined outside the ENT department.",{"count":122,"type":20},50,"Consultations for vertigo in general practice are difficult, primarily due to practitioners' lack of experience. Patient referrals can be inaccurate, leading to missed opportunities or misuse of resources. The creation of a diagnostic aid flowchart that provides referrals will improve patient care and reassure general practitioners during consultations for vertigo.",[28],[28],"2025-12-09",{"date":128,"type":40},"2025-12-23",{"date":130,"type":40},"2024-09-09",{"date":132,"type":20},"2025-12-31",{"name":134,"class":47},"University Hospital, Strasbourg, France",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":4},"100611269","evaluation-of-nystagmus-examination-using-wearable-ar-glasses-in-vertigo-patients-100611269","NCT07238387","Evaluation of Nystagmus Examination Using Wearable AR Glasses in Vertigo Patients","Evaluation of Nystagmus Examinations Conducted Using Wearable Augmented Reality Glasses in Vertigo Patients: A Randomized Equivalence Study","Inclusion Criteria:\n\n* Adults ≥18 years with vertigo\u002Fdizziness suggestive of a central or peripheral vestibular disorder.\n* Able to complete both AR-based and conventional oculomotor testing during the same visit (with \\~30-minute washout).\n* Provide written informed consent.\n* Adequate vision for eye-tracking and calibration (e.g., corrected visual acuity ≥20\u002F40 in each eye).\n* Willing and able to return for the follow-up visit.\n\nExclusion Criteria:\n\n* Use of vestibular-suppressant medications within 24 hours prior to testing (e.g., benzodiazepines, antihistamines, anticholinergics).\n* Ocular conditions that would interfere with reliable eye tracking (e.g., corrected visual acuity \\\u003C20\u002F40, dense cataract, severe ptosis\u002Fstrabismus, active ocular infection\u002Finflammation).\n* History of photosensitive epilepsy or seizure disorder triggered by visual stimuli.\n* Severe motion sickness\u002Fcybersickness or inability to tolerate the AR headset.\n* Significant cognitive impairment or psychiatric condition precluding informed consent or protocol compliance.\n* Pregnant or breastfeeding (per investigator judgment and IRB policy).\n* Any other condition that, in the investigator's opinion, would make participation unsafe or confound study results.",{"count":143,"type":20},200,[23],"Background and Purpose:\n\nVertigo is common in emergency and outpatient settings, yet standard oculomotor testing usually requires dedicated equipment and exam rooms. This study evaluates whether nystagmus examinations performed with wearable augmented-reality (AR) glasses are equivalent to conventional examination-room testing for classifying central vs. peripheral vertigo. The investigators also assess diagnostic accuracy, patient tolerability, and the reliability of AR-based interpretation (test-retest and inter-rater).\n\nStudy Design:\n\nProspective, single-center, within-subject randomized equivalence study at Kaohsiung Chang Gung Memorial Hospital. Each participant completes both AR-based and conventional oculomotor testing in a randomized order during the same visit, separated by a 30-minute washout. The study uses an evaluator-blind approach: de-identified trajectories are reviewed offline by independent experts who are masked to test modality. A follow-up visit (\\~1 week) captures adverse events and patient experience.\n\nParticipants:\n\nAdults (≥18 years) presenting with vertigo who can tolerate the AR headset and provide consent. Key exclusions include conditions that prevent reliable eye-tracking (e.g., corrected visual acuity \\\u003C20\u002F40), recent use of vestibular suppressants (within 24 hours), and other factors limiting cooperation or safety.\n\nInterventions and Procedures:\n\nThe AR system records eye movements and presents standardized visual stimuli. Conventional testing follows current clinical standards (e.g., Frenzel\u002Foculomotor exam). All recordings are stored securely for blinded review.\n\nOutcomes:\n\nPrimary endpoint: Equivalence of diagnostic agreement (central vs. peripheral) between AR-based and conventional methods, quantified by Cohen's kappa (κ) with a predefined equivalence margin.\n\nSecondary endpoints: (1) Diagnostic accuracy of the AR method in a clinically-indicated imaging subgroup (MRI preferred; CT as needed) using a sequential evaluation strategy; (2) Patient discomfort\u002Ftolerability using VAS and CSQ-VR, compared between modalities; (3) Test-retest reliability of AR-based classifications; (4) Inter-rater reliability between independent evaluators, with a third reader adjudicating discordant cases; (5) prespecified subgroup analyses by age, medical history, and vestibular function.\n\nSample Size and Duration:\n\nApproximately 200 participants will be enrolled (target \\~180 evaluable after \\~10% attrition). Total study duration is \\~2 years, including enrollment, follow-up, and analysis.\n\nRisks and Benefits:\n\nBoth tests are non-invasive. Potential transient discomfort (e.g., eye strain or cybersickness) will be monitored. There may be no direct benefit to participants; however, results could support broader, more accessible, and standardized vertigo assessment.\n\nData Security and Privacy:\n\nAll data are de-identified, stored on secure platforms with role-based access and audit trails. Safety events are monitored and graded, and protocol deviations are handled per Good Clinical Practice.",[28,147,148],"Vestibular Disorder","Nystagmus","2025-11-18",{"date":151,"type":40},"2025-11-20",{"date":153,"type":20},"2026-01-01",{"date":155,"type":20},"2029-12-31",{"name":157,"class":47},"Chang Gung Memorial Hospital",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":15,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":166,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":48},"100520884","reducing-vertigo-associated-with-mri-machines-100520884","NCT06062368","Reducing Vertigo Associated With MRI Machines","Inclusion Criteria:\n\n* Participants who will be undergoing an MRI scan at a 7 Tesla MRI.\n\nExclusion Criteria:\n\n* Exclusion criteria include pacemaker, defibrillator wires, metal implants, cochlear implants, or ferromagnetic surgical clips in the brain.\n* Pregnancy\n* Claustrophobia occurs in perhaps 5% of patients, and they will not proceed with the test. All subjects will fill out the routine pretesting MRI questionnaire.",{"count":165,"type":20},100,[23],"Vertigo, dizziness, and imbalance are commonly reported by patients and technologists when near high-field strength magnets (\\>4 Tesla, T) used for magnetic resonance imaging (MRI) (1-5) Prior research from the investigators has established that the mechanism is likely a Lorentz force occurring in the inner ear, as a result of interactions with normal electrical currents in the inner ear and the strong static magnetic field of the MRI machine. The investigators have recently developed preliminary data to suggest that slower rates of entry into the magnetic field can greatly attenuate the sensations of vertigo. The explanation for this is that the rates of vestibular adaptation exceed that of the stimulus, allowed a reduction or elimination of the symptoms of vertigo. The aim of this study is to recruit individuals who are already getting an MRI scan as part of other research studies to randomize the rate of entry into and exit from the static magnetic field (i.e., before and after imaging is performed). The usual rate of entry is 20 seconds. This will be increased to one, two or three minutes. The investigators will record subjective sensations of dizziness and vertigo associated with the entry into the MRI.",[28,27],[170,171,172],"MRI","7 Tesla","Magnetic Vestibular Stimulation","2025-11-10",{"date":175,"type":40},"2025-11-12",{"date":177,"type":40},"2024-01-15",{"date":179,"type":20},"2028-01-01",{"name":181,"class":47},"Johns Hopkins University",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":189,"enrollmentInfo":190,"targetDuration":192,"studyType":61,"phases":4,"briefSummary":193,"conditions":194,"keywords":195,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100608568","chinese-real-world-study-of-treatment-of-vestibular-migraine-100608568","NCT07203248","Chinese Real-world Study of Treatment of Vestibular Migraine","A Real-world Study on the Use of CGRP-targeted Medications for the Treatment of Vestibular Migraine in Chinese Patients","Inclusion Criteria:\n\n1. Male or female, aged between 18 and 75 years.\n2. Meet the following criteria established by the Barany Society for the diagnosis of vestibular migraine or probable vestibular migraine:\n\n   Vestibular Migraine A: At least five episodes with moderate or severe vestibular symptoms lasting from 5 minutes to 72 hours.\n\n   B: Current or past history of migraine, with or without aura, according to the International Classification of Headache Disorders (ICHD-3).\n\n   C: One or more migraine features during at least 50% of vestibular episodes:\n\n   Headache with at least two of the following characteristics: unilateral, pulsating, moderate or severe pain, worsening with routine physical activity.\n\n   Photophobia and phonophobia. Visual aura. D: Not better accounted for by another vestibular or ICHD diagnosis. Probable Vestibular Migraine A. At least five episodes with moderate or severe vestibular symptoms lasting from 5 minutes to 72 hours.\n\n   B. Meets only one of the criteria B or C for vestibular migraine (history of migraine or migraine features during episodes).\n\n   C. Not better accounted for by another vestibular or ICHD diagnosis.\n3. More than or equal to 4 days per month with confirmed vestibular symptom in the three months prior to enrollment (only required for group B).\n4. Able to complete at least 80% of the electronic diary during the treatment period.\n5. The investigator believes that the participant is able to read, understand, and complete the study questionnaires and headache diary.\n\nUnderstanding and compliance with the study procedures and methods, voluntary participation in this trial, and written informed consent.\n\nExclusion Criteria:\n\n1. Pregnant women, breastfeeding women, or those unwilling to use approved contraceptive methods during study participation.\n2. Presence of a condition or abnormality that the investigator believes would affect the safety of the patient or the quality of the data.\n3. History of ear surgery (excluding ear tube surgery).\n4. Other vestibular diagnoses (excluding treated benign paroxysmal positional vertigo, BPPV). This includes Ménière's disease, superior semicircular canal dehiscence syndrome, vestibular neuritis, persistent postural-perceptual dizziness, unilateral or bilateral vestibular hypofunction, cerebellar or brainstem disorders, multiple sclerosis, or seasickness.\n5. More than two preventive migraine medications have failed.\n6. Previous or current treatment with CGRP class drugs.\n7. History of serious medical or psychiatric conditions, as judged by the treating physician (including significant coronary artery disease, peripheral vascular disease, cerebrovascular disease, renal disease, liver disease, Raynaud's disease, uncontrolled psychiatric illness, or past psychiatric hospitalization).\n8. History of mania, psychosis, or suicidal ideation.\n9. Acceptable if using no more than two migraine preventive medications (prescribed specifically for this purpose), with stable dosing for at least 2 months prior to study start.\n10. History of drug or alcohol abuse within the 12 months prior to screening, based on the participant's medical records or self-report.\n11. Those who have received or plan to receive botulinum toxin (e.g., Dysport®, Botox®, Xeomin®, Myobloc®, Jeuveau™) for therapeutic or cosmetic purposes in the head, face, or neck within 4 months prior to screening or during the study period.","75 Years",{"count":191,"type":20},2000,"12 Weeks","Vestibular migraine is a phenotype of migraine, characterized by more prominent vertigo symptoms compared to headache. Treatments for VM are mainly divided into two categories: acute treatment and preventive treatment. Acute treatment aims to reduce the severity and duration of a single episode, while preventive treatment aims to decrease the frequency, severity, and duration of attacks. Current acute treatments are primarily divided into pain relief and anti-dizziness, with specific drugs such as triptans and ergots being applicable for pain relief, but only betahistine has weak evidence for anti-dizziness, and relevant clinical evidence is very scarce. Preventive treatment mainly refers to migraine preventive treatments, with recommended medications including traditional drugs like topiramate, flunarizine, propranolol, etc., but the efficacy and safety of these drugs are limited. CGRP-targeted drugs are believed to play a role in the preventive treatment of VM, and there are related literature reports, but most are small-sample studies or retrospective studies. This study aims to explore the real-world efficacy of CGRP-targeted drugs in the acute and preventive treatment of VM through a prospective real-world study.",[65,27,28],[65,196,197,198,199],"CGRP","acute treatment","preventive treatment","real-world","2025-09-24",{"date":202,"type":40},"2025-10-02",{"date":204,"type":20},"2025-12",{"date":206,"type":20},"2028-12",{"name":208,"class":47},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":21,"phases":218,"briefSummary":219,"conditions":220,"keywords":227,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":4},"100505635","clinical-trial-of-vit-d-and-calcium-for-recurrent-bppv-100505635","NCT05863949","Clinical Trial of Vit D and Calcium for Recurrent BPPV","STOP Vertigo: Supplementation of Vitamin D for Termination of Recurrences From Benign Paroxysmal Positional Vertigo","Inclusion Criteria:\n\n* Age 18 years or older\n* 2 or more distinct episodes of benign paroxysmal positional vertigo within a 12-month period on history\n* At least 1 episode diagnosed based on physical examination by trained study personnel, meeting the diagnostic criteria of the Bárány Society\n* Episodes separated in time, with a minimum of 1 week symptom-free between episodes\n* Serum evidence of Vitamin D deficiency, as evidenced by 25-hydroxy vitamin D level of \\\u003C75 nmol\u002FL (\\\u003C30 ng\u002FmL)48\n* Subject able to provide informed consent to participate in the study\n\nExclusion Criteria:\n\nPotential subjects will be excluded if they\n\n* have another identifiable cause of vertigo identified on history or physical examination\n* have a history of allergy or medically significant adverse reaction to vitamin D or calcium carbonate\n* have a chronic medical disorder which is a contraindication to vitamin D or calcium carbonate supplementation, including uncontrolled hyperparathyroidism, nephrolithiasis, or GI malabsorption disorders\n* are on loop diuretic agents or thiazides\n* have a contraindication to routine bloodwork for study purposes, including being hospitalized with a critical illness, cellulitis at blood draw sites, or presence of vascular grafts.",{"count":217,"type":20},860,[23],"Randomized double blind placebo controlled trial of vitamin D supplements, with or without calcium supplementation, versus placebo in reduction of recurrences in BPPV.",[221,222,28,223,27,224,225,226],"BPPV","Benign Paroxysmal Positional Vertigo","Vertigo, Peripheral","Dizziness; Epidemic","Vitamin D Deficiency","Calcium Deficiency",[228,229,230,231,232],"bppv","benign paroxysmal positional vertigo","vertigo","dizziness","vitamin D","2025-06-20",{"date":235,"type":40},"2025-06-25",{"date":237,"type":20},"2025-08",{"date":239,"type":20},"2026-09",{"name":241,"class":47},"Ottawa Hospital Research Institute",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":21,"phases":252,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":267},"100540784","phase-4-efficacy-and-safety-of-vespireit-prolonged-release-tablets-in-patients-with-autonomic-dysfunction-syndrome-accompanied-by-functional-vertigo-100540784","NCT06321341","Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo","Open-label, Multicenter, Randomized Controlled Phase 4 Trial Evaluating the Efficacy and Safety of Vespireit, Prolonged-release Tablets (Valenta Pharm JSC, Russia) Versus Arlevert, Tablets (Menarini International Operations Luxembourg S.A., Luxembourg) in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo.","Inclusion Criteria:\n\n1. Patient signed and dated the Informed Consent Form.\n2. Males and females ≥18 to ≤ 65 years of age inclusive at the time of signing the Informed Consent Form.\n3. Clinical diagnosis: G90.8 Other disorders of autonomic nervous system or G90.9 Disorder of autonomic nervous system, unspecified.\n4. Diagnosed chronic functional vertigo per Barani Society criteria: total DHI score ≥ 31 points; mean MVS score ≥ 1.5 points.\n5. For women of childbearing potential, a negative pregnancy test and consent to use an authorized method of contraception throughout the entire period of study participation, starting from Visit 0, and for 3 weeks after the end of the study; for men, consent to use an authorized method of contraception throughout the entire period of study participation and for 3 weeks after the end of the study.\n\nThe authorized contraceptive methods in this study are: intrauterine device, barrier method, or dual barrier method (condom or occlusive cap (diaphragm or cervical\u002Fvaginal cap) plus spermicide)). Hormonal contraception was not permitted due to insufficient data on drug interactions of buspirone.\n\nPostmenopausal women (≥2 years of amenorrhea) or women who are surgically sterile (hysterectomy, bilateral ovariectomy, tubal ligation)) and men with documented infertility or vasectomy will also be eligible for the study.\n\nNon-inclusion Criteria:\n\n1. Known or suspected hypersensitivity to the active substance or any of the excipients of the investigational drugs.\n2. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.\n3. A cumulative score \\> 2 on the Suicide Risk Assessment Scale (SRAS).\n4. Chronic heart failure III-IV functional classes according to the New York Heart Association (NYHA) classification, angina pectoris III-IV functional classes.\n5. Presence of uncompensated peripheral vestibular hyporeflexia due to previous vestibular neuronitis, labyrinthitis, labyrinth trauma.\n6. Presence at the time of screening of exacerbation of vestibular diseases with episodic vestibular syndrome.\n7. Meniere's disease.\n8. Established diagnosis of bilateral vestibular insufficiency.\n9. Syncopal and presyncopal conditions at the time of screening.\n10. Acute cardiovascular disease or surgical interventions (myocardial infarction, angioplasty, aortocoronary\u002Fmammary coronary heart bypass, unstable angina, and others) less than 6 months prior to the date of the Screening Visit.\n11. Acute cerebral circulatory disorders and\u002For transient ischemic attacks less than 6 months prior to the date of the Screening Visit.\n12. Hemodynamically significant cardiac rhythm and conduction abnormalities, including a history of cardiac rhythm and conduction abnormalities.\n13. An installed artificial pacemaker.\n14. Clinically significant ECG abnormalities;\n15. Established diagnosis of liver failure, including history and\u002For altered laboratory values: increase in aspartateaminotransferase (AST), alanineaminotransferase (ALT) more than 2.5 times relative to the upper limit of normal, increase in total bilirubin more than 1.5 times above the upper limit of normal;\n16. Established diagnosis of renal failure of any severity and\u002For creatinine clearance calculated by the Cockcroft-Gault formula at screening \\\u003C 80 ml\u002Fmin in women and \\\u003C 90 ml\u002Fmin in men.\n17. Pyloroduodenal obstruction based on history.\n18. Prostatic hyperplasia.\n19. Thyroid function disorder according to examination and clinical and laboratory tests.\n20. Parkinson's disease according to anamnesis.\n21. Severe ischemic heart disease.\n22. Uncontrolled hypertension with systolic blood pressure \\> 180 mm Hg and\u002For diastolic blood pressure \\> 110 mm Hg, or blood pressure (BP) at screening ≥140\u002F90 or ≤ 100\u002F60 mm Hg.\n23. Uncontrolled diabetes mellitus, diabetes mellitus in decompensation.\n24. Myasthenia gravis.\n25. Closed-angle glaucoma.\n26. Suspicion of elevated intraocular pressure at the time of screening.\n27. Systemic connective tissue diseases.\n28. Autoimmune diseases.\n29. History or suspected elevated intracranial pressure.\n30. Urinary retention due to a history of urethral and\u002For prostate disease.\n31. Need for surgical and\u002For endovascular treatment in the next 15 months.\n32. Epilepsy or convulsive seizures, including history of seizures.\n33. Alcoholism, drug dependence, substance abuse in the history and\u002For at the time of screening (alcoholism - use of more than 30 ml of ethyl alcohol per day during the last 6 months; drug dependence - use of any narcotic substances in any doses during the last 6 months; substance abuse - use of any psychoactive substances in any doses during the last 6 months).\n34. History of schizophrenia, schizoaffective disorder, bipolar disorder.\n35. Tuberculosis, hepatitis B and C, HIV infection, syphilis, history or by screening.\n36. Conditions after surgical procedures, if less than 6 months have passed since the intervention.\n37. Therapy for cognitive impairment, balance disorders, and dizziness 21 days or less prior to Visit 1-1 date.\n38. Use of an irreversible MAO inhibitor within 14 days or a reversible MAO inhibitor within 1 day prior to Visit 1-1.\n39. Therapy with the following drugs and drug groups: 7 days or less before screening: Selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and norepinephrine reuptake inhibitors (SSRIs); Cinnarizine and\u002For dimenhydrinate preparations; Cytochrome P450 3A4 (Cytochrome P450 3A4, CYP3A4) inhibitors and inducers: Erythromycin, itraconazole, nefazodone, diltiazem, verapamil, etc.; Cimetidine, warfarin, phenytoin, propranolol. Monoamine oxidase inhibitors (MAOIs): concomitant use of MAO inhibitors is prohibited, as well as taking the drug earlier than 14 days after withdrawal of an irreversible MAO inhibitor, or less than 1 day after withdrawal of a reversible MAO inhibitor.\n40. Presence of a history of malignant neoplasm, except in patients who have had no disease in the past 5 years, patients with completely cured basal cell skin cancer, or completely cured carcinoma in situ.\n41. Decompensated somatic diseases that, in the opinion of the investigator, would prevent the patient from complying with the regimen prescribed by the study protocol, or would prevent assessment of the efficacy of therapy and compliance according to the protocol, or could skew the results of the study.\n42. Decompensated neuropsychiatric diseases, including multiple sclerosis, Parkinson's disease, endogenous depression, and others, which in the opinion of the investigator would prevent the patient from complying with the regimen prescribed by the study protocol, or would prevent assessment of therapy efficacy and compliance according to the protocol, or could skew the results of the study.\n43. Female patients who are pregnant or breastfeeding or planning pregnancy within the next 15 months.\n44. Patients requiring prohibited concomitant medications.\n45. Participation in another clinical trial within the last 3 months prior to the date of the Screening Visit.\n46. Patient's unwillingness or inability to comply with protocol procedures (in the opinion of the investigator).\n47. Other conditions that, in the judgment of the investigator, preclude the patient's inclusion in the study.\n48. The patient is diagnosed with COVID-19 disease at the time of screening or Randomization Visit; or the presence of symptoms of acute respiratory infections or COVID-19 within 14 days prior to screening and a positive rapid test for COVID-19 at screening.\n\nExclusion criteria:\n\n1. The patient's decision to discontinue participation in the study.\n2. A decision by the investigator that continued participation in the study is contrary to the patient's best interests.\n3. The patient is included in the study in violation of the inclusion and non-inclusion criteria.\n4. A decision by the investigator's physician to exclude the patient from the study due to lack of adequate cooperation of the patient with the investigator's physician during the study.\n5. Diagnosis of acute (vestibular neuronitis, acute labyrinthitis, traumatic vestibulopathy, stroke with lesions of central and peripheral vestibular structures and others) and\u002For episodic vestibular syndromes (benign positional paroxysmal vertigo, Meniere's disease, vestibular migraine and others), bilateral vestibulopathy.\n6. Skipping taking the study drug (3 consecutive tablets or more than 6 tablets for each period of therapy).\n7. Omission of the active comparator (9 consecutive tablets or more than 17 tablets per therapy period).\n8. An adverse event requiring withdrawal of investigational therapy or limiting protocol procedures.\n9. The need to prescribe to the patient drugs from the \"Prohibited Concomitant Therapies\" section.\n10. Loss of communication with the patient.\n11. Pregnancy.\n12. Ineffectiveness of therapy (increase from baseline or no decrease in DHI total score and MVS mean score by 25% or more from baseline after another course of therapy).\n13. The patient was diagnosed with COVID-19 disease during the periods of primary and repeated therapy.","65 Years",{"count":251,"type":20},160,[253],"PHASE4","This study aims to evaluate the efficacy and safety of Vespireit, prolonged-release tablets, 15 mg (Valenta Pharm JSC, Russia) in comparison with Arlevert, tablets, 40 mg + 20 mg (Menarini International Operations Luxembourg S.A., Luxembourg) in patients with autonomic dysfunction syndrome accompanied by functional vertigo.",[28,256],"Autonomic Dysfunction","2025-06-11",{"date":259,"type":40},"2025-06-15",{"date":261,"type":40},"2024-01-24",{"date":263,"type":20},"2026-12-31",{"name":265,"class":266},"Valenta Pharm JSC","INDUSTRY",4,{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":15,"sex":16,"minAge":276,"maxAge":277,"enrollmentInfo":278,"targetDuration":280,"studyType":61,"phases":4,"briefSummary":281,"conditions":282,"keywords":288,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":48},"100471387","international-headache-registry-study-100471387","NCT05418218","International Headache Registry Study","International Headache and Vertigo Registration Study","IHRS","Inclusion Criteria:\n\nThe following are requirements for entry into the study:\n\n1. Written informed consent and participant privacy information (eg, Written Authorization for Use and Release of Health and Research Study Information) obtained from the participant prior to initiation of any study-specific procedures.\n2. Male or female participants ages 4 to 99 years, inclusive, at Visit 1.\n3. Headache patients meeting the diagnostic criteria for ICHD-3, including primary headaches such as migraine and tension tension-type headaches, secondary headaches, and patients who meet the headache diagnosis in the ICHD-3 appendix (including vestibular migraine).\n\nExclusion Criteria:\n\n1. Patients who were unable to complete scales such as headache diary.\n2. Patients denied or unable to be admitted for long-term follow-up.","4 Years","99 Years",{"count":279,"type":20},200000,"60 Years","In the International Headache and Vertigo Registration Study, patients aged 4-99 years with headache (primary headache and secondary headache such as migraine and tension type headache), vertigo (vertigo diseases such as vestibular migraine) and chronic pain (fibromyalgia and other diseases) were collected. The biomarkers, imaging features, right-to-left shunt of the heart (lung), genetic characteristics, treatment, and outcome (in relation to other diseases) of headache-related diseases were studied, and long-term follow-up was planned.",[283,284,285,286,28,65,287],"Headache Disorders, Primary","Headache Disorders, Secondary","Migraine","Tension-Type Headache","Fibromyalgia",[285,289,28,65,287],"Headache Disorders","2025-05-19",{"date":292,"type":40},"2025-05-23",{"date":294,"type":40},"2021-07-12",{"date":296,"type":20},"2082-12-31",{"name":208,"class":47},{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":249,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":21,"phases":307,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":340},"100493872","the-save-project-sarcopenia-and-vertigo-in-aging-patients-with-colorectal-cancer-100493872","NCT05710809","The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer","SaVe","Inclusion Criteria:\n\n* Meet the criteria of the oncological departments of receiving neoadjuvant, adjuvant or first line palliative chemotherapy for colorectal cancer\n* ≥65 years of age at the time of signing the informed consent form\n* Able to speak and read Danish, and to provide a signed informed consent form\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2\n\nExclusion Criteria:\n\n* Chemotherapy treatment within two years and sequelae of neuropathy, or symptoms of dizziness or vertigo, or balance disturbance\n* Severe physical disability that hinders physical exercise\n* Dementia, psychotic disorders, or other cognitive diseases or conditions that hinder participation in a clinical exercise-based trial\n* Inability to sign informed content\n* Patients who have had a consultation in the geriatric outpatient clinic within the past six months",{"count":306,"type":20},150,[23],"The goal of this clinical trial is to learn about the cause of dizziness and decline in walking ability in in older adults ≥65 years during chemotherapy treatment for colorectal cancer. Another goal is to investigate if a comprehensive geriatric assessment and three months' specialized physical group-based exercise three times\u002Fweek can counteract muscle weakness, vertigo, instability, impaired walking balance, and neuropathy",[310,311,312,313,314,315,28,316,317,318,319,320,321,322,323,324,325,326,327,328,329,330],"Colorectal Cancer","Oncologic Complications","Comprehensive Geriatric Assessment","Vestibular Rehabilitation","Geriatric Oncology","Sarcopenia","Cancer","Rehabilitation","Exercise","Geriatric","Elderly","Frail","Older Adults","Chemotherapy","Chemotherapy-induced Peripheral Neuropathy","Resistance Training","Balance Training","Postural Stability","Pragmatic Trial","Personal Medicine","Individualised","2025-04-02",{"date":333,"type":40},"2025-04-06",{"date":335,"type":40},"2023-02-20",{"date":337,"type":20},"2027-09",{"name":339,"class":47},"Rigshospitalet, Denmark",2,{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":249,"maxAge":189,"enrollmentInfo":348,"targetDuration":4,"studyType":21,"phases":349,"briefSummary":350,"conditions":351,"keywords":352,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":363,"locationsCount":340},"100574568","effects-of-vestibular-habituation-and-ocular-reflex-exercises-on-vertigo-100574568","NCT06760975","Effects of Vestibular Habituation and Ocular Reflex Exercises on Vertigo","Comparative Effects of Vestibular Habituation and Ocular Reflex Exercises on Gait Stability, Dizziness Severity, and Fear of Fall in Elderly Population With Vertigo","Inclusion Criteria:\n\n1. Both male and female patients\n2. Age 65-75\n3. patient with vestibular disorder for at least 6 months\n4. patient with unspecific dizziness sensation for at least 3 months\n5. Dizziness handicap inventory score \\> 16 -\n\nExclusion Criteria:\n\n1. patient with central nervous system diseases, like stroke, multiple sclerosis, Parkinson's disease.\n2. orthopedic problems that precluded performance of the exercises\n3. systemic diseases with no medication control\n4. if patient were legally blind or had dementia\n5. patient with no history of epilepsy and other neurological diseases -",{"count":122,"type":20},[23],"The aim of this study is to determine the comparative effects of vestibular Habituation and ocular reflex exercises on Gait stability, Dizziness severity, and fear of fall in elderly population with vertigo",[28],[230,353,354,355,356],"Habituation","Ocular reflex","Fear of fall","Gait stability","2025-01-01",{"date":359,"type":40},"2025-01-07",{"date":361,"type":20},"2024-12-31",{"date":237,"type":20},{"name":364,"class":47},"Riphah International University",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":16,"minAge":371,"maxAge":280,"enrollmentInfo":372,"targetDuration":4,"studyType":21,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":48},"100572865","effect-of-wii-fit-training-in-comparison-to-vestibular-rehabilitation-training-on-balance-in-patients-with-benign-paroxysmal-postional-vertigo-100572865","NCT06738823","Effect of Wii Fit Training in Comparison to Vestibular Rehabilitation Training on Balance in Patients With Benign Paroxysmal Postional Vertigo","Inclusion Criteria:\n\n* Patients diagnosed with benign paroxysmal positional vertigo.\n* Aged 30-60 years.\n* Ability to stand and walk independently.\n* Male and Female\n* Positive Dix Hallpike Test\n* DHI Scale: 36-42 (moderate Handicap)\n\nExclusion Criteria:\n\n* patients with history of vestibular surgery or cochlear implantation.\n* Patients with history of seizures or epilepsy.\n* patients with a pacemaker or implantable cardioverter-defibrillator(ICD).\n* Patients with history of severe head injury or concussion within the past year.\n* No other vestibular disorders or conditions that may affect balance.","30 Years",{"count":373,"type":20},38,[23],"THIS STUDY IS A RANDOMIZED CONTROL TRIAL AND THE PURPOSE OF THE STUDY IS TO DETERMINE THE EFFECT OF WIIFIT TRAINING IN COMPARISON TO VESTIBULAR REHAB TRAINING ON BALANCE IN PATIENTS WITH BENIGN PAROXYSMAL POSITIONAL VERTIGO",[222,377,28],"Balance","2024-12-13",{"date":380,"type":40},"2024-12-18",{"date":382,"type":40},"2024-07-20",{"date":384,"type":20},"2024-12-20",{"name":386,"class":47},"Foundation University Islamabad",{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":15,"sex":16,"minAge":57,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":21,"phases":396,"briefSummary":397,"conditions":398,"keywords":402,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":4},"100567489","quantitative-eye-movement-measurements-in-patients-with-acute-vestibular-syndrome-100567489","NCT06668857","Quantitative Eye Movement Measurements in Patients with Acute Vestibular Syndrome","Oculomotor Profile in Acute Vestibular Syndrome - Value of Saccades, Pursuit Eye Movements and Pupillary Reflexes in Differentiating Central and Peripheral Causes","Inclusion Criteria:\n\n* Patient groups\n\n  * patients presenting with an AVS (peripheral or central), with symptom duration of 5 days or less\n  * being able to receive brain MRI\n* All groups:\n\n  * Being able to give informed consent as documented by signature\n  * Age 18 years or above\n\nExclusion Criteria:\n\n* Aged less than 18 years.\n* Pregnant or lactating women\n* Inability or contraindications to undergo the investigated intervention (including brain MRI in the patient groups),\n* Clinically significant concomitant diseases such neurodegenerative disorders (e.g. Alzheimer's disease, Parkinson's disease)\n* Pre-existing peripheral-vestibular \u002F central-vestibular deficits\n* History of brainstem \u002F cerebellar stroke\n* Pre-existing or acute severe visual loss\n* Pre-existing severe hearing loss.\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, aphasia.",{"count":395,"type":20},75,[23],"BACKGROUND: A chief complaint of acute vertigo\u002Fdizziness is related to about 2.1-7.1% of all emergency department (ED) visits. About 25% of all patients with acute prolonged vertigo meeting diagnostic criteria of AVS (acute vestibular syndrome) suffer from a vertebrobasilar stroke and about 35% of these patients are initially missed. Differentiating dangerous central from more benign peripheral causes of AVS is essential. Subtle oculomotor paradigms such as HINTS (Head-Impulse, Nystagmus, Test-of-Skew) have been shown to detect central causes with high diagnostic accuracy, however, require sufficient training. Thus, identifying other bedside tests that can be reliably performed by frontline providers is essential to reduce misdiagnosis.\n\nWORKING HYPOTHESIS: By using additional oculomotor (saccades, pursuit) and pupillomotor parameters at the bedside or quantitatively, the diagnostic accuracy for distinguishing peripheral from central AVS causes can be further improved, especially in the setting when expertise for applying more sophisticated algorithms (HINTS(+), STANDING) is lacking.\n\nAIM 1: Detecting changes in oculomotor and pupillomotor responses in acutely dizzy patients and characterizing the spectrum of abnormalities in peripheral and central AVS.\n\nAIM 2: Comparing different composite oculomotor-\u002Fpupillomotor scores to identify those scores with the highest diagnostic accuracy at the bedside and quantitatively.\n\nAIM 3: Comparing the diagnostic accuracy of bedside and quantitative oculomotor and pupillomotor testing in AVS- identifying potential limitations of bedside testing.\n\nMETHODS: To assess oculomotor and pupillomotor responses in patients with peripheral or central AVS and healthy controls (25 participants each) at the bedside and quantitatively by use of a Pioneer research eye tracker (PRET) system and to compare the diagnostic accuracy of individual and composite responses.\n\nEXPECTED VALUE OF THE PROJECT: The proposed project will shed more light on the value of different examination techniques in AVS for distinguishing peripheral from central causes. This is achieved by investigating oculomotor and pupillomotor parameters obtained at the bedside and quantitatively in the acute stage and at follow-up. The insights gained will likely have a direct impact on diagnostic accuracy and thus on future strategies how to evaluate acutely dizzy patients in the ED. Eventually, this may reduce the rate of misdiagnosis and may improve patients' outcome.",[399,28,400,401],"Acute Vestibular Syndrome","Stroke Acute","Acute Unilateral Vestibulopathy (AUV)",[230,231,403,404,405,406],"acute vestibular syndrome","stroke","vestibular neuritis","diagnostic accuracy","2024-10-30",{"date":409,"type":40},"2024-10-31",{"date":411,"type":20},"2025-07-01",{"date":413,"type":20},"2028-06-30",{"name":415,"class":47},"Alexander Tarnutzer",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":16,"minAge":249,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":21,"phases":426,"briefSummary":427,"conditions":428,"keywords":429,"overallStatus":103,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":48},"100565083","effects-of-brandt-daroff-exercises-in-older-adults-with-vertigo-100565083","NCT06637566","Effects of Brandt Daroff Exercises in Older Adults With Vertigo","Effects Of Brandt Daroff Exercises With Cawthorne Cooksey Exercises On Balance, Dizziness And Functional Parameters In Older Adults With Vertigo","Inclusion Criteria:\n\n* Older adults 65or above.\n* Both Male and Female.\n* Symptoms suggested vertigo, confirmed by neurologist.\n* Accepted to participate in study.\n* DHI Scale: 36-42 (moderate handicap).\n\nExclusion Criteria:\n\n* Patients having balance issues other than dizziness and vertigo.\n* Middle or external ear diseases.\n* Cerebrovascular diseases.\n* Feet injuries including severe bruises, ulcers, open wounds or recent burns.\n* Neck pain and cervical spine disease.\n* History of serious musculoskeletal disease (arthritis, Alzheimer's disease, intervertebral disc degeneration).","80 Years",{"count":425,"type":20},32,[23],"Vertigo is among the most prevalent disorder in older adults around the world leads to dizziness and balance problems resulting in decreased quality of life. Brandt daroff exercises can accelerate vertigo recovery and prevent recurrence without taking drugs. Cawthorne Cooksey first presented vestibular exercises to improve neurophysiological habituation, improves balance in the elderly. This study aims to determine the effects of brandt daroff exercises with cawthorne cooksey exercises on balance, dizziness and functional parameters in older adults with vertigo.",[28],[430,431,432,433],"Vertigo,","balance","functional parameters","dizziness,","2024-10-10",{"date":436,"type":40},"2024-10-15",{"date":438,"type":20},"2024-10-08",{"date":440,"type":20},"2025-01-03",{"name":364,"class":47},{"id":443,"slug":444,"hasResults":11,"nctId":445,"briefTitle":446,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":15,"sex":16,"minAge":57,"maxAge":280,"enrollmentInfo":448,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":449,"conditions":450,"keywords":451,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":48},"100533621","cohort-study-of-clinical-and-neuroimaging-characteristics-for-bppv-patients-in-china-100533621","NCT06228196","Cohort Study of Clinical and Neuroimaging Characteristics for BPPV Patients in China","Inclusion Criteria:\n\n* Confirmed diagnosis of BPPV\u002FHealthy subjects who have not had BPPV\n\nExclusion Criteria:\n\n* History of organic diseases in central nervous system and mental disorder, such as tumors, infections, depressive disorder, schizophrenia, etc. Claustrophobic",{"count":306,"type":20},"The main objective is to analyze the abnormality of physical condition, mental health and blood examination of the patients with benign paroxysmal positional vertigo (BPPV). Besides, the investigators aim to establish a database of BPPV based on multimodal magnetic resonance imaging data in the brain to identify high-risk patients with residual dizziness (RD) and systematically establish the comprehensive assessment system for the precise diagnosis, treatment and recovery of RD, optimize the tactics of BPPV management in China.",[221,28,223],[221,452,28,453,454],"residual dizziness","Neuroimaging","Epidemic","2024-02-22",{"date":457,"type":40},"2024-02-26",{"date":459,"type":40},"2024-01-08",{"date":461,"type":20},"2026-09-30",{"name":463,"class":47},"First Affiliated Hospital Xi'an Jiaotong University"]